Immunotherapy Agents Leading Advancements in Metastatic Bladder Cancer
October 10th 2017The therapeutic landscape is rapidly being altered by clinical trials of immunotherapy for patients with metastatic urothelial carcinoma, but simply changing the way quality of life is monitored could provide dramatic improvements in overall survival.
IMRT Linked With Low Rates of Pelvic Recurrence in Bladder Cancer
October 6th 2017Delivering IMRT to the bladder and pelvic nodes in patients with node-positive bladder cancer or high-risk node-negative bladder cancer is feasible with patients experiencing low toxicity and demonstrating low pelvic nodal rates of recurrence
New Bladder Cancer Monitor Allows Non-invasive Routine Surveillance of NMIBC
October 6th 2017A new procedure for monitoring RNA indicators of disease recurrence in urine samples from patients with a history of non-muscle invasive bladder cancer could spare these patients from undergoing multiple cystoscopies during routine follow-up.
Chemotherapy Retains Vital Role in Bladder Cancer Care
October 6th 2017Although immunotherapy shows great promise in meeting the need for effective treatment of muscle invasive bladder cancer, chemotherapy continues to be an important tool in treating patients with this disease and other forms of bladder and urothelial cancer.